Brief: RNAGENE Signs Collaborative Research Agreement With PharmAbcine To Develop Novel MRNA Therapeutics
21/03/2022 13:38
March 21 (Reuters) - PharmAbcine Inc 208340.KQ :
* RNAGENE SIGNS A COLLABORATIVE RESEARCH AGREEMENT WITH
PHARMABCINE TO DEVELOP NOVEL MRNA THERAPEUTICS
* RNAGENE INC - COS WILL COLLABORATE TO DEVELOP MRNA-BASED
ANTIBODY THERAPEUTICS BY UTILIZING PROPRIETARY MRNA PLATFORM
FROM RNAGENE
Source text for Eikon: ID:nPnbd3dgsa
Further company coverage: 208340.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration